{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T06:10:07Z","timestamp":1745215807186,"version":"3.40.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515220041"],"award-info":[{"award-number":["2021A1515220041"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-97084-2","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T05:39:46Z","timestamp":1745213986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of Boolean2.0 remission in rheumatoid arthritis identified using smart disease management system data"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9741-6891","authenticated-orcid":false,"given":"Yuqi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keqian","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1882-3932","authenticated-orcid":false,"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8698-8915","authenticated-orcid":false,"given":"Yongfu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6241-9868","authenticated-orcid":false,"given":"Hua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxue","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peijun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianlin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"97084_CR1","doi-asserted-by":"crossref","unstructured":"Aletaha, D. & Smolen, J. S. Diagnosis and management of rheumatoid arthritis. JAMA 320(13) (2018).","DOI":"10.1001\/jama.2018.13103"},{"issue":"1","key":"97084_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 82(1), 3\u201318 (2023).","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"97084_CR3","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.3899\/jrheum.090980","volume":"37","author":"W Katchamart","year":"2010","unstructured":"Katchamart, W. & Bombardier, C. Systematic monitoring of disease activity using an outcome measure improves outcomes in rheumatoid arthritis. J. Rhuematol. 37(7), 1411\u20131415 (2010).","journal-title":"J. Rhuematol."},{"key":"97084_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"JS Smolen","year":"1995","unstructured":"Smolen, J. S. et al. Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38, 44\u201348 (1995).","journal-title":"Arthritis Rheum."},{"key":"97084_CR5","doi-asserted-by":"crossref","unstructured":"Aletaha, D. et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score. Arthritis Res. Therapy 7(4) (2005).","DOI":"10.1186\/ar1740"},{"issue":"2","key":"97084_CR6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","volume":"42","author":"JS Smolen","year":"2003","unstructured":"Smolen, J. S. et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42(2), 244\u2013257 (2003).","journal-title":"Rheumatology"},{"issue":"3","key":"97084_CR7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson, D. T. et al. American college of rheumatology\/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann. Rheum. Dis. 70(3), 404\u2013413 (2011).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"97084_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/ard-2022-223413","volume":"82","author":"P Studenic","year":"2023","unstructured":"Studenic, P. et al. American college of rheumatology\/eular remission criteria for rheumatoid arthritis: 2022 revision. Ann. Rheum. Dis. 82(1), 74\u201380 (2023).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"97084_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 75(1), 3\u201315 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"97084_CR10","doi-asserted-by":"crossref","unstructured":"Sun, X. et al. Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region. Lancet Reg. Health Western Pac. 15 (2021).","DOI":"10.1016\/j.lanwpc.2021.100240"},{"issue":"6","key":"97084_CR11","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s10067-023-06548-1","volume":"42","author":"A Khabbazi","year":"2023","unstructured":"Khabbazi, A. et al. Prevalence and predictors of long-term remission in rheumatoid arthritis in real-world practice: A longitudinal study. Clin. Rheumatol. 42(6), 1537\u20131544 (2023).","journal-title":"Clin. Rheumatol."},{"key":"97084_CR12","unstructured":"Li, C. et al. Management of rheumatoid arthritis with a digital health application. JAMA Netw. Open. 6(4) (2023)."},{"issue":"5","key":"97084_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.reuma.2010.11.006","volume":"7","author":"M Robustillo Villarino","year":"2011","unstructured":"Robustillo Villarino, M. & Rodriguez Moreno, J. Are useful prognostic factors in rheumatoid arthritis? Reumatol Clin. 7(5), 339\u2013342 (2011).","journal-title":"Reumatol Clin."},{"issue":"8","key":"97084_CR14","first-page":"1670","volume":"34","author":"L Mancarella","year":"2007","unstructured":"Mancarella, L. et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: The GISEA study. J. Rhuematol. 34(8), 1670\u20131673 (2007).","journal-title":"J. Rhuematol."},{"issue":"4","key":"97084_CR15","doi-asserted-by":"publisher","first-page":"e0214981","DOI":"10.1371\/journal.pone.0214981","volume":"14","author":"YK Sung","year":"2019","unstructured":"Sung, Y. K. et al. Prevalence and predictors for sustained remission in rheumatoid arthritis. PLoS ONE. 14(4), e0214981 (2019).","journal-title":"PLoS ONE"},{"issue":"2","key":"97084_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/rheumatology\/key054","volume":"58","author":"JT Einarsson","year":"2019","unstructured":"Einarsson, J. T. et al. Prevalence of sustained remission in rheumatoid arthritis: Impact of criteria sets and disease duration, a nationwide study in Sweden. Rheumatology 58(2), 227\u2013236 (2019).","journal-title":"Rheumatology"},{"issue":"25","key":"97084_CR17","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee, E. B. et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl. J. Med. 370(25), 2377\u20132386 (2014).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"97084_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13075-023-03199-0","volume":"25","author":"MM Ward","year":"2023","unstructured":"Ward, M. M., Madanchi, N., Yazdanyar, A., Shah, N. R. & Constantinescu, F. Prevalence and predictors of sustained remission\/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: A systematic and scoping review. Arthritis Res. Ther. 25(1), 222 (2023).","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"97084_CR19","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1093\/rheumatology\/key202","volume":"57","author":"N Paulshus Sundlisaeter","year":"2018","unstructured":"Paulshus Sundlisaeter, N. et al. Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. Rheumatology 57(11), 2022\u20132031 (2018).","journal-title":"Rheumatology"},{"issue":"1","key":"97084_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13075-015-0707-1","volume":"17","author":"G Nagy","year":"2015","unstructured":"Nagy, G. & van Vollenhoven, R. F. Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now? Arthritis Res. Ther. 17(1), 181 (2015).","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"97084_CR21","doi-asserted-by":"publisher","first-page":"e000993","DOI":"10.1136\/rmdopen-2019-000993","volume":"5","author":"K Chatzidionysiou","year":"2019","unstructured":"Chatzidionysiou, K. & Sfikakis, P. P. Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: Review of randomised controlled trials could point towards a paradigm shift. RMD Open 5(2), e000993 (2019).","journal-title":"RMD Open"},{"issue":"4","key":"97084_CR22","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/annrheumdis-2012-202735","volume":"73","author":"K Horslev-Petersen","year":"2014","unstructured":"Horslev-Petersen, K. et al. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA study: An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann. Rheum. Dis. 73(4), 654\u2013661 (2014).","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"97084_CR23","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/ard.59.11.841","volume":"59","author":"F Breedveld","year":"2000","unstructured":"Breedveld, F. & Dayer, J. Leflunomide: Mode of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 59(11), 841\u2013849 (2000).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"97084_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12891-017-1673-3","volume":"18","author":"H Wijesinghe","year":"2017","unstructured":"Wijesinghe, H. et al. Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: Results from a randomized double blind controlled clinical trial. BMC Musculoskelet. Disord. 18(1), 310 (2017).","journal-title":"BMC Musculoskelet. Disord."},{"issue":"1","key":"97084_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12891-018-2302-5","volume":"19","author":"CD Hughes","year":"2018","unstructured":"Hughes, C. D., Scott, D. L., Ibrahim, F. & Investigators, T. P. Intensive therapy and remissions in rheumatoid arthritis: A systematic review. BMC Musculoskelet. Disord. 19(1), 389 (2018).","journal-title":"BMC Musculoskelet. Disord."},{"issue":"1","key":"97084_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s42358-021-00205-4","volume":"61","author":"JM Stacy","year":"2021","unstructured":"Stacy, J. M., Greenmyer, J. R., Beal, J. R., Sahmoun, A. E. & Diri, E. The efficacy of low dose short-term prednisone therapy for remission induction in newly diagnosed rheumatoid arthritis patients. Adv. Rheumatol. 61(1), 50 (2021).","journal-title":"Adv. Rheumatol."},{"issue":"2","key":"97084_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1136\/annrheumdis-2011-201067","volume":"72","author":"F Buttgereit","year":"2013","unstructured":"Buttgereit, F. et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: A randomised clinical trial (CAPRA-2). Ann. Rheum. Dis. 72(2), 204\u2013210 (2013).","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"97084_CR28","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1002\/art.42292","volume":"74","author":"B Seppen","year":"2022","unstructured":"Seppen, B. et al. Smartphone-assisted patient-initiated care versus usual care in patients with rheumatoid arthritis and low disease activity: A randomized controlled trial. Arthritis Rheumatol. 74(11), 1737\u20131745 (2022).","journal-title":"Arthritis Rheumatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97084-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97084-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97084-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T05:39:49Z","timestamp":1745213989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97084-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["97084"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-97084-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved and monitored by the Committee on Scientific Research and Ethics of the Sixth Affiliated Hospital of Sun Yat-sen University (No. 2024ZSLYEC-121). Informed consent was obtained from all the patients enrolled in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}}],"article-number":"13676"}}